[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"basic-science\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:basic-science":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,66,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100445367","neural-basis-of-sensory-learning-brain-regions-100445367",false,"NCT05079516","Neural Basis of Sensory Learning: Brain Regions","Inclusion Criteria:\n\n* Potential subjects must be between the ages of 18-45 years old and right-handed. Aging has been shown to affect the morphology of sensory and motor nerves, conduction velocities of nerves, and number of motor neurons in the spinal cord; to avoid these confounding factors we will only examine younger-to middle-aged adults.\n* There are differences in cortical function and corticospinal projections such that testing the right arm of a right-handed individual is not necessarily equivalent to testing the left arm of a left-handed individual. To eliminate this confound, we will only test right-handed individuals. All these factors will be determined with the initial screening questions.\n* Covid has been found to have neurological effects in some people, but mostly the effects on sensorimotor control and neurophysiology are unknown. So we want to reduce the chances of inadvertently testing subjects who have covid. We will therefore only include individuals who are fully vaccinated (2+ weeks past their final vaccine dose) or have a negative Covid test within 4 days of testing. We will further only include individuals who report being free of Covid symptoms in week preceding testing.\n\nExclusion Criteria:\n\n1. Determined with initial screening questions, pre-enrollment:\n\n   Potential subjects will be excluded for current vision problems, other than needing glasses or contacts. Subjects will also be excluded if they currently suffer from frequent severe headaches, glaucoma, heart or respiratory disease, hypertension, psychiatric conditions, or learning or attention conditions. They will also be excluded for current or past: visual, hearing, or balance impairments; stroke, seizure\u002Fepilepsy (including family history), or severe head trauma; fainting; or diabetes. Subjects will be excluded for metal implants in the head other than titanium; cochlear implants; implanted neurostimulator; cardiac pacemaker; intracardiac lines; or a medication infusion device. Because TMS does not penetrate deeply into the head, we cannot test subjects whose hair does not permit contact between the TMS coil and the scalp. We will therefore exclude subjects with dreadlocks, weaves, or hair extensions. To protect the data from extraneous peripheral influences, we will also exclude subjects who have had serious injury to the bones, joints, or muscles of either hand or arm, and have not fully recovered. For the purpose of this study, \"fully recovered\" means they no longer notice any pain, weakness, or loss of sensation in the injured area, and have no mobility limitations.\n\n   For the validity of our data, we will exclude subjects taking medications or drugs that are known to affect cortical excitability and possibly seizure risk in an rTMS study. These medications\u002Fdrugs are (Rossi et al., 2009): imipramine, amitriptyline, doxepine, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel's dust), ketamine, gamma-hydroxybutyrate (GHB), theophylline, mianserin, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, reboxetine, venlafaxine, duloxetine, bupropion, mirtazapine, fluphenazine, pimozide, haloperidol, olanzapine, quetiapine, aripiprazole, ziprasidone, risperidone, chloroquine, mefloquine, imipenem, penicillin, ampicillin, cephalosporins, metronidazole, isoniazid, levofloxacin, cyclosporin, chlorambucil, vincristine, methotrexate, cytosine arabinoside, BCNU, lithium, anticholinergics, antihistamines, sympathomimetics.\n2. Determined on each day of TMS testing:\n\n   Potential subjects will be invited to reschedule if they would otherwise be eligible (according to the initial screening), but the day of testing have drunk more than 3 units of alcohol or taken other recreational drugs in the 24 hour period prior to testing; have had more than 3 cups of coffee in the last hour; are sleep deprived (\\\u003C4 hours sleep the previous night); or have participated in another brain stimulation experiment the same day. These are standard in the TMS literature to protect the validity of the data and keep seizure risk minimal. In addition, we will invite invite subjects to reschedule if they have any of the common Covid symptoms within the last week and if they haven't been fully vaccinated or obtained a negative Covid test within the past 4 days. If they don't believe they can meet these criteria on another date, they will be excluded.\n3. Determined during the Familiarization session.\n\nAfter giving their consent, participants may be excluded during or after the familiarization session if they are unable to perform the reaching task or follow instructions, or if their TMS stimulation parameters cannot be reliably determined by the experimenter, or if TMS is not well tolerated.",true,"ALL","18 Years","45 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to understand how the sensory and motor areas of the brain work together to keep a person's hand movements accurate (sensorimotor learning). The investigators hope this information may be useful one day to improve rehabilitation techniques in patients with brain lesions.",[27],"Basic Science","RECRUITING","2026-04-28",{"date":31,"type":32},"2026-05-04","ACTUAL",{"date":34,"type":32},"2021-10-26",{"date":36,"type":21},"2026-12",{"name":38,"class":39},"Indiana University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100628334","phase-1-a-mass-balance-study-of-14c-ray1225-injection-in-healthy-chinese-participants-100628334","NCT07460284","A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants","A Mass Balance Study of 14C-RAY1225 Injection in Healthy Chinese Participants","Inclusion Criteria:\n\n1. Participants who sign the informed consent form, fully understand the content, process, and possible adverse reactions of the study, and are able to complete the study as required by the study protocol;\n2. Healthy adult males aged 18-55 years (inclusive, based on the time of signing the ICF);\n3. Weight ≥ 50 kg, and body mass index (BMI) = weight (kg)\u002Fheight2 (m 2) between 20.0-35.0 kg\u002Fm2 (inclusive);\n4. Participants (including partners) who agree to voluntarily use effective contraception from screening until 6 months after the investigational drug administration and have no sperm donation plan. For specific contraceptive measures\n\nExclusion Criteria:\n\n1. Subjects with trauma, surgical scar, or skin lesions at the proposed administration site (abdomen) who are not suitable for subcutaneous injection as assessed by the investigator;\n2. History of hypoglycemic episodes within 12 months prior to screening;\n3. Major surgery or serious infection within 12 weeks prior to screening;\n4. Acute disease from the signing of the ICF to the administration of the investigational drug;\n5. Smoking more than 5 cigarettes per day within 12 weeks prior to screening, or unable to abstain from smoking within 7 days prior to admission and during the study;\n6. Participants who are not otherwise eligible to participate in this study.","55 Years",{"count":50,"type":21},8,[52],"PHASE1","This is an open-label, single-center, single-dose study.",[27],"NOT_YET_RECRUITING","2026-03-03",{"date":58,"type":32},"2026-03-10",{"date":60,"type":21},"2026-03-15",{"date":62,"type":21},"2026-10-28",{"name":64,"class":65},"Guangdong Raynovent Biotech Co., Ltd","INDUSTRY",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":40},"100468029","factors-affecting-sensory-and-motor-learning-100468029","NCT05374460","Factors Affecting Sensory and Motor Learning","Inclusion Criteria:\n\n* Between the ages of 18-45 years old\n* Right-handed.\n* Covid has been found to have neurological effects in some people, but mostly the effects on sensorimotor control and neurophysiology are unknown. So we will only include individuals who report being free of Covid symptoms in week preceding testing.\n\nExclusion Criteria:\n\n* Past or present history of seizure, stroke, any brain or peripheral nerve disease, severe head trauma, or spinal cord surgery.\n* Learning or attention conditions such as ADHD.\n* Orthopedic or pain conditions, or a history of seriously injured bones, joints or muscles in either arm.\n* Lack of normal or corrected-to-normal vision.",{"count":20,"type":21},[24],"How participants perceive the position of their own hand in various contexts will be examined. This will include changing the visual display to suggest the hand is in a slightly different position, and asking participants to indicate where they think it is by pointing with their other hand.",[27],"2025-08-20",{"date":78,"type":32},"2025-08-26",{"date":80,"type":32},"2022-04-29",{"date":82,"type":21},"2027-04-30",{"name":38,"class":39},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":40},"100308027","phase-1-the-neurobiological-effect-of-5-ht2ar-modulation-100308027","NCT03289949","The Neurobiological Effect of 5-HT2AR Modulation","NeuroPharm2","Inclusion Criteria:\n\n1\\) Healthy individuals above 18 years of age.\n\nExclusion Criteria (For Subprojects 1, 2a, 2b, and 3):\n\n1. Presence of or previous primary psychiatric disease (DSM axis 1 or WHO ICD-10 diagnostic classifications) or in first-degree relatives.\n2. Previous or present neurological condition\u002Fdisease, significant somatic condition\u002Fdisease or intake of drugs suspected to influence test results.\n3. Non-fluent Danish language skills.\n4. Vision or hearing impairment.\n5. Previous or present learning disability.\n6. Pregnancy.\n7. Breastfeeding.\n8. Contraindications in regard to MRI scanning.\n9. Alcohol or drug abuse.\n10. Allergy to test drugs.\n11. Participation in studies in which participant has received more than 10 mSv of radiation or other significant exposure to radiation.\n12. Abnormal ECG or intake of QT prolonging medication.\n13. Previous significant side-effects in regard to hallucinogenic drugs.\n14. Use of hallucinogenic drugs 6 months previous to inclusion.\n15. Blood donation 3 months before and after project participation\n16. Body weight under 50 kg.\n17. Plasma ferritin levels outside normal range\n\nExclusion Criteria (For Subproject 2c):\n\n1. Presence of or previous primary psychiatric disease (DSM IV axis 1 or WHO ICD-10 diagnostic classifications).\n2. Presence of or previous primary psychiatric disease with psychosis symptoms or hypomania (DSM IV axis 1 \\[drug\u002Falcohol abuse\u002Fdependence, schizophrenia and other psychoses\\] or WHO ICD-10 diagnostic classifications \\[F10-29, as well as F30-39 with psychotic symptoms, F60\\]) in first-degree relatives (parents or siblings).\n3. Previous or present neurological condition\u002Fdisease, significant somatic condition\u002Fdisease or intake of drugs suspected to influence test results.\n4. Non-fluent Danish language skills or pronounced vision or hearing impairment.\n5. Previous or present learning disability.\n6. Pregnancy.\n7. Breastfeeding.\n8. Contraindications in regard to MRI scanning.\n9. Alcohol or drug abuse.\n10. Allergy to test drugs.\n11. Abnormal ECG or intake of QT prolonging medication.\n12. Previous significant side-effects in regard to hallucinogenic drugs.\n13. Previous use of hallucinogenic drugs.\n14. Body weight under 45 kg.\n15. Ethical concerns regarding the administration of a psychedelic drug.",{"count":92,"type":21},200,[52],"The investigators wish to investigate neurobiological effects of serotonin 2A receptor modulation in healthy volunteers, contrasting effects of an agonist (psilocybin) and an antagonist (ketanserin). Magnetic resonance imaging (MRI) and positron emission tomography (PET) will be used as neuroimaging tools.",[27],"2024-12-13",{"date":98,"type":32},"2024-12-16",{"date":100,"type":32},"2017-03-03",{"date":102,"type":21},"2030-06-01",{"name":104,"class":39},"Gitte Moos Knudsen"]